Sotorasib shows meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

UF Health was a study location for a multicenter phase 1-2 trial showing that the KRAS G12C inhibitor sotorasib achieved anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer.

Thomas George
Thomas George, M.D., FACP

Thomas George, M.D., FACP, a professor of the division of hematology & oncology in the University of Florida College of Medicine, was a coauthor on the study, published in January in the New England Journal of Medicine. George also serves as associate director for clinical research at the UF Health Cancer Center and director of the GI Oncology Program at UF.

The study reported an objective response rate of 21.1% and a median time-to-response of 1.5 months, with 84% of patients experiencing disease control. Median progression-free survival was 4 months and overall survival was 6.9 months. The study population comprised 38 patients across multiple centers.

The CodeBreaK 100 trial was funded by Amgen. The work was also supported in part by the National Institutes of Health (P30 CA008748, P30 CA016672, 1UL1 TR003167), the Cancer Prevention and Research Institute of Texas (RP150535), and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at MD Anderson Cancer Center.

READ MORE IN THE NEW ENGLAND JOURNAL OF MEDICINE.